Ariana Boswell

Ariana Boswell received her bachelor's degree in biochemistry from Vassar College and is currently pursuing her Master of Public Health in epidemiology at Columbia University Mailman School of Public Health. She has previously conducted research on rare and chronic diseases at Vassar College and Yale School of Medicine and hopes to remain involved in rare disease research and communications in the future. Ariana joined Rare Disease Advisor in 2024.

All articles by Ariana Boswell

Can children get bladder cancer?

Most cases of childhood bladder cancer are low grade and have a good prognosis.
Five or more BCG maintenance therapy doses may lower cancer recurrence risk

Receiving five or more installations of Bacillus Calmette−Guérin maintenance therapy within one year may improve bladder cancer survival.
Understanding TURBT: Tumor removal surgery for bladder cancer

TURBT removes tumors from the bladder, and is often the first step in bladder cancer management.
New data suggests UGN-102 offers long-lasting benefits in bladder cancer

A Phase 3 clinical trial of UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cancer supports its long-term efficacy.
The side effects to expect from radiation for bladder cancer

The side effects of radiation can be challenging, but prioritizing your well-being can help make them more manageable.
Robot-assisted cystectomy 101: What patients with bladder cancer should know

Robot-assisted surgery often means a shorter hospital stay, reduced risk of infection and a less painful recovery.
Combination treatment improves survival in cisplatin-eligible MIBC

Pembrolizumab and enfortumab vedotin reduce the risk of death, progression or recurrence in muscle invasive bladder cancer, Pfizer shared.
When to get a second opinion after a bladder cancer diagnosis

Whether you’ve just been diagnosed or have already undergone treatment, it’s never too late to think about seeking a second opinion.
Women may face worse outcomes after chemo-radiation for bladder cancer

Among patients receiving chemo-radiation for muscle-invasive bladder cancer, females had worse cancer-specific survival than males.
What is muscle-invasive bladder cancer?

About 25% of bladder cancer cases are muscle-invasive.